September 22, 2025 2025 Q3 Economic Factors and J&J Announcements Below is a high-level summary of current macro-economic factors, notable announcements made this quarter, as well as public commentary made by management during the quarter and recent earnings calls. Any additional information included herein is provided as phasing considerations and should not be construed as guidance. Phasing considerations: In addition to the comments provided during the Q2 earnings call, please note the following: • As a reminder, we acquired Shockwave in May of 2024. This marks the first full quarter where Shockwave is reflected in both current and prior year results, allowing for a direct comparison. • For your convenience, as we progress through 2025, we have attached QTD and FY segment P&Ls for 2024. Macro-economic factors: • Supply Chain / Inflationary Pressures: Elevated inflation rates continued throughout Q3 with July CPI at 2.7% and August CPI at 2.9%. • Interest Rates: The Federal Funds Rate continues to impact the financing cost of our commercial paper as well as interest income on our cash position. • Tariffs: in Q2 we noted a 2025 impact of $200M, exclusively related to our MedTech business, based on tariff information known at that time. We continue to monitor tariffs and their potential impact to our business. • Global Affairs: As described in our Form 10-K risk factors, we have experienced, and expect to continue to experience, impacts to the Company's business resulting from the Russia-Ukraine war, rising conflict in the Middle East as well as increasing tensions between the U.S. and China. • Foreign Exchange: We don’t offer guidance or predictions on currency movements, but as highlighted by Joe during the Q2 2025 earnings call, we utilized the Euro Spot Rate relative to the U.S. dollar as of mid-July of 1.17 to give a sense of the potential impact on Full Year 2025 guidance. The Euro Spot Rate averaged 1.17 in July, 1.16 in August, and 1.18 through mid-September. As a reminder, our results are based on a basket of currencies, of which, not all align to the Euro. Conference participation J&J conference participation (transcripts and webcasts) throughout the quarter can be found here. Transcripts for the events below have been attached for your convenience. • Wells Fargo 2025 Healthcare Conference: Tim Schmid - Executive Vice President Worldwide Chairman, MedTech, fireside chat with Larry Biegelsen - Wells Fargo Securities, LLC, Analyst • Morgan Stanley 23rd Annual Global Healthcare Conference: Joaquin Duato - Chairman and Chief Executive Officer and John Reed - Executive Vice President, Innovative Medicine, Research and Development, fireside chat with Terence Flynn – Morgan Stanley, Analyst -- 1 of 5 -- Announcements Press releases issued during the quarter can be found on the J&J Media Center, Innovative Medicine Newsroom, and MedTech News & Events page. • M&A: N/A • Talc: please visit factsabouttalc.com for the latest company statements • Innovative Medicine: o Alzheimer’s: AAIC curtain raiser o DARZALEX: EC approval for smoldering multiple myeloma o Fetal immunology: ISUOG curtain raiser o Icotrokinra: US FDA NDA submission; Phase 3 ICONIC studies o IMBRUVICA: EC approval in frontline MCL o INLEXZO (TAR-200): US FDA Approval; US FDA Priority Review for TAR-200 NDA o RYBREVANT+LAZCLUZE: Phase 3 MARIPOSA resistance data; Phase 3 MARIPOSA OS data o TECVAYLI & DARZALEX FASPRO: Phase 2 MajesTEC efficacy data o TREMFYA: US FDA supplemental sBLA submission; UC SubQ approval o Other: 2025 Psych Congress abstracts • MedTech: o Abiomed: DanGer Shock Data o EP: VARIPURE Substudy of SECURE results o ORTHO: VIRTUGUIDE™ Launch o Shockwave: Javelin Launch in Europe • Other Notable Announcements: o Organizational announcement: John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, is elected to the Johnson & Johnson Board of Directors -- 2 of 5 -- J&J earnings calls: • Q2 2025 earnings call: Full year 2025 Operational Sales Guidance excluding the COVID-19 Vaccine of $92.7B - $93.1B or 4.5% - 5.0% and Adjusted Operational Earnings Per Share of $10.63 - $10.73 or 6.5% - 7.5% was provided on our Q2 2025 Earnings Call. Please see the below 2025 Phasing Considerations slide from the earnings presentation. For your convenience, the final Q2 2025 earnings transcript and presentation are attached. Full Q2 2025 earnings call operational commentary and key drivers can be listened to here and the Q2 2025 10-Q can be found here. • Q3 2024 earnings call: For ease of reference, below are related sales and EPS absolute figures and growth rates for Q3 2024. Full Q3 2024 operational commentary, key drivers, and one-timers can be listened to here and the Q3 2024 10-Q can be found here. For your convenience, the final Q3 2024 earnings transcript and presentation are attached. o Enterprise: $22.5B, 6.3% operational sales growth and 5.4% adjusted operational sales growth  Enterprise sales highlights can be found on page 4 of the final Q3 2024 earnings transcript attached  P&L highlights can be found on pages 5-6 of the final Q3 2024 earnings transcript attached o Innovative Medicine: $14.6B, 6.3% operational sales growth  Innovative Medicine sales highlights can be found on page 4 of the final Q3 2024 earnings transcript attached o MedTech: $7.9B, 6.4% operational sales growth  MedTech sales highlights can be found on page 5 of the final Q3 2024 earnings transcript attached -- 3 of 5 -- -- 4 of 5 -- -- 5 of 5 --